Supplements

Across the pooled trials, vitamin D was associated with small reductions in blood markers of bone turnover. The featured trial did not detect a statistically significant difference in either marker. These are laboratory outcomes: the abstract does not report whether fractures were reduced, so the marker changes cannot establish a fracture-prevention benefit.

Keep in mind: This brief is based on the abstract alone. It does not describe participant characteristics or pooled follow-up durations, limiting assessment of who the pooled findings represent and over what period.

The review found statistically significant improvements in vaginal dryness and urinary and genital symptoms with soy isoflavones. Results for vasomotor and psychological symptoms were inconclusive, and findings varied substantially across trials. This supports a cautious, symptom-specific interpretation without establishing a preferred dose or showing that improvements persist over the long term.

Keep in mind: The abstract describes safety favorably but gives no adverse-event results or follow-up lengths. This abstract-based account also lacks comparator-specific estimates, and high study variation limits generalization.

The authors reported improvements in macular pigment and best-corrected visual acuity, mainly in early-stage age-related macular degeneration. A statistically significant benefit was not demonstrated in late-stage disease, leaving that subgroup uncertain. The reported measurements do not establish how large or lasting any improvement in everyday vision would be.

Keep in mind: The abstract omits treatment lengths and confidence intervals, and does not define how its pooled effects compare groups or time points. This abstract-based explanation therefore cannot establish the size or practical meaning of the reported improvements.

Vitamin E supplementation increased maternal blood concentrations of alpha-tocopherol, the vitamin E marker measured in this review. That laboratory change did not come with clear improvements in birth weight or gestational age at birth. The findings separate a nutritional-status result from newborn clinical outcomes and leave the practical benefit of supplementation uncertain.

Keep in mind: The evidence ranged from low to moderate certainty, and maternal blood-level results varied substantially across trials. This abstract-based summary cannot resolve the differing study findings or assess an appropriate supplementation regimen.

The pooled trials suggest that nitrate-rich beetroot juice may improve exercise capacity in people with COPD. That conclusion was less consistent when trials were separated by design: parallel trials showed a benefit, while crossover results were uncertain. Blood pressure was also lower overall, but these findings do not establish lasting improvements in daily functioning.

Keep in mind: The abstract does not describe the control treatments or study durations. Although the review assessed evidence certainty, it does not report those ratings, and the authors call for standardized, longer-term studies.

Rats given Bacopa before a temporary interruption of brain blood flow had better motor and spatial-memory test results, less brain tissue damage and more favorable antioxidant measurements than rats with the induced injury alone. These findings concern pretreatment in a laboratory model. They do not establish that Bacopa prevents or treats stroke in people.

Keep in mind: The abstract provides no group sizes, numerical outcome estimates or uncertainty intervals. Treatment preceded the injury, so the experiment cannot establish what happens when Bacopa is started after a stroke.

Beta-alanine did not clearly improve repeated sprint ability compared with placebo. The pooled results were nonsignificant for average performance, peak performance and fatigue decrement, meaning the fall in performance across sprints. These findings do not prove there is no effect, and they apply to repeated sprinting rather than exercise performance in general.

Keep in mind: The abstract does not provide individual protocols or evidence-certainty ratings. This abstract-based account cannot fully assess confidence in the pooled results.

After the intervention, the betaine-containing nutrient group had greater improvements in homocysteine, several blood sugar and lipid measures, and selected body measurements than the vitamin comparison group. Both groups improved on multiple outcomes. These findings concern people with excess weight and elevated homocysteine; they do not establish reduced cardiovascular disease or benefits for the general population.

Keep in mind: The abstract does not specify the nutrient formulation, doses or absolute between-group changes. This abstract-based account therefore cannot isolate betaine's contribution or judge the clinical importance of the reported statistical differences.

In this pilot trial, the lower-dose creatine arm showed a greater improvement in fatigue scores than placebo, alongside a handgrip-strength improvement. Everyone also took part in physical activity. The abstract does not give corresponding outcome estimates for the higher-dose arm, so it cannot establish which dose performed better or whether benefits persist.

Keep in mind: This abstract-based summary covers a short pilot trial with incomplete follow-up. Results for the higher-dose arm are not detailed, and minimal, temporary adverse events do not establish long-term safety.

Inositol supplementation was associated with lower testosterone and related measures of excess androgen activity in women with PCOS. Results varied substantially across studies. The clearest subgroup signal appeared in women of normal weight, but those analyses were exploratory. The abstract does not establish improvements in unwanted hair growth, ovulation or patients' day-to-day experience.

Keep in mind: Treatment comparators and durations are not described in the abstract. Substantial variation between studies and exploratory subgroup analyses limit confidence in how the findings apply to individual patients.

The combination showed a greater reduction in morning blood pressure measured at home, while clinic measurements fell in both groups. Some blood fat and insulin-related markers also improved, but fasting glucose, HbA1c and quality-of-life scores did not change. These results concern a combined supplement and measured risk markers, rather than demonstrated prevention of cardiovascular events.

Keep in mind: The abstract does not clearly separate changes within the supplement group from differences versus placebo for most markers. The combination design cannot identify the separate contribution of either ingredient.

The higher vitamin D dose did not show superior improvement in depressive symptoms when added to existing treatment. The estimated difference was small, and its confidence interval included no difference. This result does not prove the doses are equivalent or establish whether either dose helps compared with taking no vitamin D.

Keep in mind: This abstract-based brief cannot explain why some participants lacked outcome data. Because both groups received vitamin D, the trial also cannot establish a benefit compared with no supplementation.

The pooled analysis did not find a statistically significant change in weight with spirulina supplementation in children and adolescents. That result does not establish that spirulina has no effect on growth. Only a small part of the eligible evidence contributed to the pooled estimate, and the studies differed substantially in their findings and delivery.

Keep in mind: The abstract does not name comparison conditions, summarize intervention durations or give participant totals. The pooled weight estimate was imprecise, with a confidence interval spanning zero, and differences between studies limit a single overall conclusion.

Vitamin D supplementation improved walking-test distance, breathlessness scores and fatigue scores compared with placebo in men with stable COPD and low vitamin D. Ventilation measures reportedly did not improve. These findings concern a narrowly defined patient group; without the size of the changes, their practical importance is difficult to judge.

Keep in mind: This abstract-based summary has significance tests but no distances, score changes or confidence intervals. The small trial involved only men who smoked and had low vitamin D, and it does not report safety outcomes.

Participants receiving the herbal mixture were more likely than those receiving placebo to have an improved fatty liver grade on ultrasound by the study's end. This was a preliminary result from a small trial. An imaging-grade improvement does not establish lasting recovery, prevention of liver complications or a benefit from any single ingredient.

Keep in mind: This abstract-based summary reflects a small study at one center with short follow-up. Mild adverse events occurred at similar rates, but these findings do not establish long-term effectiveness or safety.

Animal studies of Dang Gui Shao Yao San reported improved spatial learning and memory performance, alongside changes related to oxidative stress, in models of vascular dementia. The review provides preliminary evidence for further laboratory research. It does not establish whether the formula improves symptoms, slows dementia or is safe in people.

Keep in mind: The authors reported substantial differences across outcome measures and generally low methodological quality. The abstract provides no effect sizes, treatment durations or comparator details, leaving the size and reliability of the animal findings uncertain.

The review describes favorable findings from trials of ashwagandha and rhodiola across stress, anxiety, sleep and several other outcomes. However, it does not separate those findings clearly by plant, population or comparison group. That makes it difficult to judge the size, consistency or practical importance of any benefit from the abstract alone.

Keep in mind: The authors identify varied methods, short interventions and small samples as limitations. The abstract supplies no outcome-specific effect estimates, confidence intervals or safety results, so it cannot support broad claims of effectiveness or long-term safety.

A standardized purple perilla leaf extract produced greater improvements on cognitive tests than placebo in adults with cognitive impairment. Both groups improved, and the extract group improved more. Blood measures of amyloid beta and brain-derived neurotrophic factor did not differ significantly between groups, so the test findings do not establish an effect on those biomarkers.

Keep in mind: The abstract reports statistical significance without effect sizes or confidence intervals. Short-term test-score changes do not establish lasting benefit or improved daily functioning, and the safety summary cannot establish safety over longer use.

The review describes how plant extracts may affect stress signaling and reports lower cortisol, less fatigue and better cognitive function in clinical studies. The abstract does not identify which extracts produced those outcomes or how consistent the results were. These reports cannot establish that a particular adaptogen product treats stress-related illness.

Keep in mind: The abstract omits study counts, participant details, trial lengths and extract-specific effect estimates. Its claim that clinical studies reported no adverse effects comes without safety data that would allow readers to assess that conclusion.

Creatine ranked highest for muscle strength, protein for endurance, and omega-3 for recovery in this network meta-analysis. These rankings concern different outcomes in trained athletes. The abstract does not name the reference group for each reported effect estimate or describe supplementation periods, leaving the practical size of any advantage unclear.

Keep in mind: This abstract-based account cannot establish dose-specific effects or lasting performance changes: doses, follow-up lengths and detailed recovery endpoints are missing. The comparator behind each numerical effect estimate is also unspecified.

The pooled analysis reported reductions in delayed muscle soreness and several inflammation and muscle injury markers after exercise with EPA and DHA supplementation. C-reactive protein results were more variable. These findings concern soreness and biological markers; the abstract does not present direct performance results establishing better long-term athletic performance or faster functional recovery.

Keep in mind: The abstract does not identify the control conditions or provide endpoint-specific estimates with confidence intervals. It also omits participant totals, trial quality assessments, and the full range of supplementation durations.

This abstract-based review did not find support for metabolic benefits from olive leaf extract or oleuropein in pooled continuous-intake trials. Short-term studies gave mixed results that could not be pooled, and evidence on inflammation was limited. The findings do not establish that every formulation or use pattern has no effect.

Keep in mind: The abstract provides no pooled effect estimates, confidence intervals, doses, or treatment lengths. Evidence on inflammatory markers was scarce and rated low certainty.

This abstract-based trial did not show that vitamin K2 improved strength, physical function, soreness, or inflammatory responses during recovery from muscle-damaging exercise. Some measures of muscle activation and blood markers varied with age and treatment, but those signals did not establish better recovery in older adults. They warrant further investigation.

Keep in mind: The abstract gives no effect sizes or confidence intervals for the main recovery outcomes. Age-related marker differences had unclear patterns and do not establish a functional benefit.

In this trial, survivors taking the standardized ginseng extract had lower fatigue scores than those taking placebo by the end of treatment, after accounting for baseline fatigue. Several aspects of daily functioning also improved. The findings support a short-term effect in this selected survivor group, while longer-lasting benefits and safety remain uncertain.

Keep in mind: This abstract-based summary covers a small, short trial. The abstract gives no extended follow-up, and the absence of reported treatment-related adverse events does not rule out uncommon or delayed harms.